15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Fulgent Genetics Inc, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $15.00 to $30.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $22.50 sits 15% above the current $19.64. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.37 next quarter toward $-1.53 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Fulgent Genetics Inc.
As of Jul, 1 of 2 firms rate FLGT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
FLGT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.37
Range $-0.38 – $-0.36 · 2 analysts · -363% YoY
Next period, 2 analysts expect Fulgent Genetics Inc to earn $-0.37 a share (range $-0.38 – $-0.36), versus $0.14 a year earlier. Full-year consensus is $-1.57, growing to $-1.53 the year after.
REVENUE · NEXT QUARTER
$93.8M
Range $92.7M – $94.9M · 2 analysts · +12% YoY
Revenue is expected to reach $93.8M (range $92.7M – $94.9M), +11.6% year-over-year. Full-year consensus is $350.9M, rising to $402.3M next year.
Top analysts covering Fulgent Genetics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FLGT.
#1
David Westenberg
Piper Sandler · Rank #227
Hold
$15.00-23.6% to target
Overall win rate
31%
+ Follow
#2
LL
Lu Li
UBS
Buy
$22.00+12.0% to target
Coverage
—
+ Follow
#3
Andrew Cooper
Raymond James
Buy
$25.00+27.3% to target
Coverage
—
+ Follow
FLGT stock forecast FAQ
What is FLGT's average 12-month price target?+
The 2 analysts with a live target average $22.50 for Fulgent Genetics Inc over the next 12 months, ranging from a $30.00 high to a $15.00 low.
Is FLGT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for FLGT?+
The Street-high target is $30.00 (UBS), and the Street-low is $15.00 (Piper Sandler). The average of all 2 active targets is $22.50.
How many Wall Street analysts cover FLGT?+
2 analysts have an active rating on Fulgent Genetics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering FLGT?+
Among analysts who currently cover FLGT, David Westenberg of Piper Sandler has the strongest overall Quantellect track record (Rank #227). Their current call is Hold with a $15.00 target.
What is Fulgent Genetics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.37 per share (range $-0.38 – $-0.36) across 2 analysts. Full-year EPS is projected at $-1.57, rising to $-1.53 the following year.
How much revenue is Fulgent Genetics Inc expected to report next quarter?+
Consensus revenue is $93.8M (range $92.7M – $94.9M). Full-year revenue is projected at $350.9M, growing to $402.3M next year.
Have analysts been upgrading or downgrading FLGT lately?+
As of Jul, 1 of 2 firms rate FLGT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FLGT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
